ISSUE 1551
| The full article is available to subscribers | Subscriber Login |
The FDA has approved axicabtagene ciloleucel (Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. It is the second CAR T-cell immunotherapy to become available in the US. Tisagenlecleucel (Kymriah), a CAR T-cell product previously approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients ≤25 years old,1 was recently also approved for relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy.
TREATMENT OF LARGE B-CELL LYMPHOMA — Most cases of diffuse large B-cell lymphoma, the most
... more- Tisagenlecleucel (Kymriah) for ALL. Med Lett Drugs Ther 2017; 59:177.
- M Crump et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130:1800.
- SS Neelapu et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377:2531.
- DW Lee et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124:188.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. www.fdbhealth.com/policies/drug-pricing-policy.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1551f
Electronic, downloadable article - $45
